Product Center
Ab&B Bio-Exhibition Wrapped Up Successfully
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23
- Views:
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.
Ab&B Bio-Exhibition Wrapped Up Successfully
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23 10:20
- Views:
From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.
Ab&B Bio-Tech Co., Ltd. (JS) participated in the exhibition with China’s first quadrivalent influenza virus subunit vaccine (HRK-X®). During the meeting, the staff provided a detailed introduction to the company and its products for experts and scholars from medical and healthcare institutions, research institutes, and colleges and universities across China, highlighting the characteristics of the subunit influenza vaccine, which extracts only the effective antigens, hemagglutinin and neuraminidase, through the structure of the influenza virus, and garnered widespread attention and positive feedback.
This conference featured a number of parallel sessions, such as “50 Years of Global EPI – The Road to China”, in which more than 160 renowned experts from China shared their academic achievements on hot topics in the fields of vaccine research and development, vaccination-based prevention, and disease prevention and control. Among them, in the session report on “Progress and Application of Vaccine Clinical Trials”, Director Pan Hongxing from the Vaccine Clinical Evaluation Institute of Jiangsu CDC presented on the “Progress of Clinical Evaluation of New Domestic Influenza Vaccines”, covering the current status of influenza vaccine application in China and globally, interim safety data from the Phase III clinical study of the new domestic quadrivalent subunit influenza vaccine, and related scientific research projects of the National Center for Evaluation.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
